Johnson & Johnson Boosts U.S. Investments to $55B
Expansion Amid Tariff Threats Johnson & Johnson (JNJ.N) announced plans to increase its U.S. investments by 25% to more than $55 billion over the next four years. The move comes as the
Eli Lilly’s Q4: Strong Drug Demand, But Sales Miss Target
Eli Lilly posted a mixed earnings report for the fourth quarter, with strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro driving revenue growth. However, sales slightly missed
